Medications for Acid Sphingomyelinase Deficiency (ASMD)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Acid Sphingomyelinase Deficiency (ASMD).
Found 1 Approved Drug for Acid Sphingomyelinase Deficiency (ASMD)
Xenpozyme
Generic Name
Olipudase Alfa-Rpcp
Xenpozyme
Generic Name
Olipudase Alfa-Rpcp
Form: Injection
Method of administration: Intravenous
FDA approval date: August 29, 2022
XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. XENPOZYME is a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. ( 1 )
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances